Study agents | Other agents | Disease | Dosage | Clinical trials | No.of Pts | Response | Reference |
---|---|---|---|---|---|---|---|
Lenalidomide | Â | Relapsed | 5/10/15 mg | Phase II | 95 | CR:2% | [34] |
Refractory | ORR:79% | ||||||
Lenalidomide | Dexamethasone | Untreated | 5Â mg | Phase II | 18 | CR:6% | [35] |
ORR:59% | |||||||
Lenalidomide | Fludarabine | Untreated | 2.5Â mg | Phase I/II | 64 | CR:11% | [36] |
Rituximab | Minimally | Â | Â | Â | ORR:63% | Â | |
 |  | treated |  |  |  |  |  |